Wuhan Easy Diagnosis Biomedicine Co Ltd
SZSE:002932
Intrinsic Value
Wuhan Easy Diagnosis Biomedicine Co., Ltd. is engaged in the manufacturing and selling of the Diagnosis Biomedicine related equipment. [ Read More ]
The intrinsic value of one
Wuhan Easy Diagnosis Biomedicine Co Ltd
stock under the Base Case scenario is
106.09
CNY.
Compared to the current market price of 20 CNY,
Wuhan Easy Diagnosis Biomedicine Co Ltd
is
Undervalued by 81%.
Wuhan Easy Diagnosis Biomedicine Co Ltd's market capitalization is 4.6B CNY.
Wuhan Easy Diagnosis Biomedicine Co Ltd stock price is 20 CNY.
Wuhan Easy Diagnosis Biomedicine Co Ltd stock price (20 CNY) is 81% less than its Intrinsic Value (106.09 CNY).
Wuhan Easy Diagnosis Biomedicine Co Ltd stock price (20 CNY) is 90% less than its DCF Value (193.74 CNY). Open DCF Valuation
Wuhan Easy Diagnosis Biomedicine Co Ltd stock (18.43 CNY) is 8% less than its price (20 CNY). Open Relative Valuation
Wuhan Easy Diagnosis Biomedicine Co Ltd.
Wuhan Easy Diagnosis Biomedicine Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 8%.
Wuhan Easy Diagnosis Biomedicine Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 14%.
Wuhan Easy Diagnosis Biomedicine Co Ltd's Revenue has dropped by 56% over the past 12 months.
Wuhan Easy Diagnosis Biomedicine Co Ltd's ROE (Return on Equity) has significantly decreased in the last 3 years from 78% to 8%.
Wuhan Easy Diagnosis Biomedicine Co Ltd's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 169% to 14%.
Wuhan Easy Diagnosis Biomedicine Co Ltd has positive Operating Income for the last twelve months.
Wuhan Easy Diagnosis Biomedicine Co Ltd has positive Net Income for the last twelve months.
Wuhan Easy Diagnosis Biomedicine Co Ltd has positive Gross Profit for the last twelve months.
Wuhan Easy Diagnosis Biomedicine Co Ltd's Altman Z-Score is very high and is equal to 3.51.
Wuhan Easy Diagnosis Biomedicine Co Ltd's short-term assets (5B CNY) exceed its short-term liabilties (2B CNY).
Wuhan Easy Diagnosis Biomedicine Co Ltd has positive Free Cash Flow for the last twelve months.
Wuhan Easy Diagnosis Biomedicine Co Ltd's Revenue has been growing by an exceptional 76% per year for the last 3 years.
Wuhan Easy Diagnosis Biomedicine Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.06.
Wuhan Easy Diagnosis Biomedicine Co Ltd has very high three-year average ROE (Return on Equity): 67%. The company is very efficient at transforming stockholders' equity into net income.
Wuhan Easy Diagnosis Biomedicine Co Ltd has very high three-year average ROIC (Return on Invested Capital): 127%. The company is very efficient at using invested capital to generate operating income.
Wuhan Easy Diagnosis Biomedicine Co Ltd's long-term assets (8B CNY) exceed its long-term liabilties (2B CNY).
Wuhan Easy Diagnosis Biomedicine Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (2B CNY) than debt (344m CNY).
Valuation Backtest
Wuhan Easy Diagnosis Biomedicine Co Ltd
Run backtest to discover the historical profit from buying and selling
Wuhan Easy Diagnosis Biomedicine Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Wuhan Easy Diagnosis Biomedicine Co Ltd
Balance Sheet Decomposition
Wuhan Easy Diagnosis Biomedicine Co Ltd
| Current Assets | 4.9B |
| Cash & Short-Term Investments | 2.2B |
| Receivables | 2.3B |
| Other Current Assets | 345.5m |
| Non-Current Assets | 3.1B |
| Long-Term Investments | 2.4B |
| PP&E | 571.3m |
| Intangibles | 17.4m |
| Other Non-Current Assets | 186.3m |
| Current Liabilities | 1.6B |
| Accounts Payable | 809.5m |
| Accrued Liabilities | 270.8m |
| Short-Term Debt | 323.2m |
| Other Current Liabilities | 170.4m |
| Non-Current Liabilities | 355.8m |
| Long-Term Debt | 21m |
| Other Non-Current Liabilities | 334.7m |
Earnings Waterfall
Wuhan Easy Diagnosis Biomedicine Co Ltd
|
Revenue
|
3.7B
CNY
|
|
Cost of Revenue
|
-2B
CNY
|
|
Gross Profit
|
1.6B
CNY
|
|
Operating Expenses
|
-1B
CNY
|
|
Operating Income
|
613.5m
CNY
|
|
Other Expenses
|
-98.2m
CNY
|
|
Net Income
|
515.3m
CNY
|
Free Cash Flow Analysis
Wuhan Easy Diagnosis Biomedicine Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Wuhan Easy Diagnosis Biomedicine Co Ltd's profitability score is 78/100. The higher the profitability score, the more profitable the company is.
Score
Wuhan Easy Diagnosis Biomedicine Co Ltd's profitability score is 78/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Wuhan Easy Diagnosis Biomedicine Co Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Score
Wuhan Easy Diagnosis Biomedicine Co Ltd's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Wuhan Easy Diagnosis Biomedicine Co Ltd
Shareholder Return
Price
Wuhan Easy Diagnosis Biomedicine Co Ltd
| Average Annual Return | 39.19% |
| Standard Deviation of Annual Returns | 45.69% |
| Max Drawdown | -83% |
| Market Capitalization | 4.6B CNY |
| Shares Outstanding | 232 521 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Wuhan Easy Diagnosis Biomedicine Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Wuhan Easy Diagnosis Biomedicine Co., Ltd. is engaged in the manufacturing and selling of the Diagnosis Biomedicine related equipment. The company is headquartered in Wuhan, Hubei and currently employs 1,144 full-time employees. The company went IPO on 2018-07-10. The firm's main products are POCT rapid diagnostic reagents, which can be divided into six categories: infectious diseases, cardiovascular and cerebrovascular diseases, kidney diseases, diabetes, gynecology and eugenics, and health checkups. The firm's main products are mainly used in domestic hospitals, health service centers, community clinics, medical examination centers and other medical institutions.
Contact
IPO
Employees
Officers
The intrinsic value of one
Wuhan Easy Diagnosis Biomedicine Co Ltd
stock under the Base Case scenario is
106.09
CNY.
Compared to the current market price of 20 CNY,
Wuhan Easy Diagnosis Biomedicine Co Ltd
is
Undervalued by 81%.
You don't have any saved screeners yet
